- Home
- ZLAB vs APLS Comparison
ZLAB vs APLS Comparison
Compare ZLAB & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- APLS
- Stock Information
- Founded
- ZLAB 2013
- APLS 2009
- Country
- ZLAB China
- APLS United States
- Employees
- ZLAB N/A
- APLS N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- ZLAB Health Care
- APLS Health Care
- Exchange
- ZLAB Nasdaq
- APLS Nasdaq
- Market Cap
- ZLAB 3.2B
- APLS 2.9B
- IPO Year
- ZLAB 2017
- APLS 2017
- Fundamental
- Price
- ZLAB $20.98
- APLS $20.06
- Analyst Decision
- ZLAB Buy
- APLS Buy
- Analyst Count
- ZLAB 6
- APLS 19
- Target Price
- ZLAB $57.22
- APLS $32.83
- AVG Volume (30 Days)
- ZLAB 899.6K
- APLS 3.3M
- Earning Date
- ZLAB 11-06-2025
- APLS 10-30-2025
- Dividend Yield
- ZLAB N/A
- APLS N/A
- EPS Growth
- ZLAB N/A
- APLS N/A
- EPS
- ZLAB N/A
- APLS 0.36
- Revenue
- ZLAB $441,629,000.00
- APLS $1,016,397,000.00
- Revenue This Year
- ZLAB $40.71
- APLS $25.39
- Revenue Next Year
- ZLAB $50.42
- APLS N/A
- P/E Ratio
- ZLAB N/A
- APLS $56.08
- Revenue Growth
- ZLAB 24.14
- APLS 42.11
- 52 Week Low
- ZLAB $20.61
- APLS $16.10
- 52 Week High
- ZLAB $44.34
- APLS $35.72
- Technical
- Relative Strength Index (RSI)
- ZLAB 21.54
- APLS 38.50
- Support Level
- ZLAB $21.59
- APLS $19.65
- Resistance Level
- ZLAB $22.28
- APLS $20.70
- Average True Range (ATR)
- ZLAB 0.86
- APLS 1.27
- MACD
- ZLAB -0.18
- APLS -0.26
- Stochastic Oscillator
- ZLAB 6.41
- APLS 11.86
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.